VERAXA Biotech GmbH

Velabs Therapeutics (www.velabs-therapeutics.com), is a spin-off company founded by Europe's most renowned life science research institute, the European Molecular Biology Laboratory (EMBL, www.embl.de) and its technology transfer arm EMBLEM Technology Transfer (EMBLEM, www.embl.em.de).

The institute has an outstanding track record in instrument development and is a world leader in microfluidic-based screening technology and application. Company investor is Xlife Sciences Ltd. (www.xlifesciences.ch), a Swiss company focusing on the performance of promising life science technologies. XLife cooperates with industrial partners and universities, leads projects through the proof of concept phase and offers investors the advantage of a very early and direct entry into the further development of innovative, future-oriented technologies.
Velabs is a pioneer in microfluidic technology for the screening of antibodies with modulatory function on complex signaling proteins such as GPCRs or ion channels.

The high-throughput screening platform makes it possible to test millions of correctly paired, natural human and murine IgGs for their therapeutic effects and not just for their binding. Results are achieved in a fraction of the time required by other technologies. The company offers customized screening services to users worldwide. In addition to conducting service projects, Velabs is currently building its own pipeline of therapeutic antibody candidates for further joint development with pharmaceutical partners.

Further information on the websites of BIOPRO Baden-Württemberg: